Trial Profile
A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Shigella flexneri 2A vaccine (Primary)
- Indications Shigella infections
- Focus Adverse reactions; Pharmacodynamics
- 24 Oct 2016 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 24 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.
- 31 Dec 2015 Planned End Date changed from 1 Dec 2017 to 1 Sep 2017, as reported by ClinicalTrials.gov.